by newtreeway | May 29, 2018
–Study suggests that novel oral formulation of edaravone improves bioavailability while remaining well tolerated– Rotterdam, The Netherlands, May 29th2018 – Treeway, a biotech company developing therapies against amyotrophic lateral sclerosis (ALS),...
by newtreeway | Mar 21, 2018
This week, the Australian Motor Neurone Disease Symposium takes place in Melbourne, Australia. Our CEO, Inez de Greef-van der Sandt, will present the clinical development of TW001 by Treeway...
